Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle T Amber

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Frontiers in Medicine|July 26, 2018
The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous DiseaseKyle T Amber, Manuel Valdebran, Khalaf Kridin, et al.
Frontiers in Immunology|June 24, 2025
Editorial: Innate immune dysregulation: a driving force of autoimmunity and chronic inflammationReza Akbarzadeh, Jens Y Humrich, Tamás Németh, et al.
Journal of the American Academy of Dermatology|April 4, 2019
Comment on "Incidence of pneumocystosis among patients exposed to immunosuppression"Eric H Kowalski, Diana Kneiber, Khalaf Kridin, et al.
Dermatologic Therapy|April 13, 2019
Pemphigus subtype: a confounder in determining the association of oral involvement with post-rituximab relapsesDiana Kneiber, Eric H Kowalski, Khalaf Kridin, et al.
International Journal of Colorectal Disease|December 31, 2015
Granulomatosis with polyangiitis (GPA) initially presenting as sigmoiditis with the later development of spontaneous subcapsular hematomaKyle T Amber, Ann Bunyan, John J Lee, et al.
The American Journal of Dermatopathology|July 11, 2017
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief"Larisa M Lehmer, Kyle T Amber, Sébastien M de Feraudy
The British Journal of Dermatology|February 10, 2023
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort studyKhalaf Kridin, Noor Mruwat, Kyle T Amber, et al.
The British Journal of Dermatology|September 13, 2023
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapyChristian F Guerrero-Juarez, Parul K Goyal, Kyle T Amber
Drugs|September 22, 2018
Targeted Therapies for Autoimmune Bullous Diseases: Current StatusKyle T Amber, Roberto Maglie, Farzan Solimani, et al.
Journal of Skin Cancer|June 24, 2014
Assessing the current market of sunscreen: a cross-sectional study of sunscreen availability in three metropolitan counties in the United StatesKyle T Amber, Romi Bloom, Patrick Staropoli, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Frontiers in Medicine|July 26, 2018
The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous DiseaseKyle T Amber, Manuel Valdebran, Khalaf Kridin, et al.
Frontiers in Immunology|June 24, 2025
Editorial: Innate immune dysregulation: a driving force of autoimmunity and chronic inflammationReza Akbarzadeh, Jens Y Humrich, Tamás Németh, et al.
Journal of the American Academy of Dermatology|April 4, 2019
Comment on "Incidence of pneumocystosis among patients exposed to immunosuppression"Eric H Kowalski, Diana Kneiber, Khalaf Kridin, et al.
Dermatologic Therapy|April 13, 2019
Pemphigus subtype: a confounder in determining the association of oral involvement with post-rituximab relapsesDiana Kneiber, Eric H Kowalski, Khalaf Kridin, et al.
International Journal of Colorectal Disease|December 31, 2015
Granulomatosis with polyangiitis (GPA) initially presenting as sigmoiditis with the later development of spontaneous subcapsular hematomaKyle T Amber, Ann Bunyan, John J Lee, et al.
The American Journal of Dermatopathology|July 11, 2017
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief"Larisa M Lehmer, Kyle T Amber, Sébastien M de Feraudy
The British Journal of Dermatology|February 10, 2023
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort studyKhalaf Kridin, Noor Mruwat, Kyle T Amber, et al.
The British Journal of Dermatology|September 13, 2023
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapyChristian F Guerrero-Juarez, Parul K Goyal, Kyle T Amber
Drugs|September 22, 2018
Targeted Therapies for Autoimmune Bullous Diseases: Current StatusKyle T Amber, Roberto Maglie, Farzan Solimani, et al.
Journal of Skin Cancer|June 24, 2014
Assessing the current market of sunscreen: a cross-sectional study of sunscreen availability in three metropolitan counties in the United StatesKyle T Amber, Romi Bloom, Patrick Staropoli, et al.
Pageof 15